Methods and Results We studied 429 consecutive in-hospital patients who met the following inclusion criteria: history of chest pain, off antianginal therapy for at least 2 days (1 week for p-blockers), no previous myocardial infarction and/or obvious regional left ventricular dyssynergy of contraction (akinesis or dyskinesis) at baseline, and acceptable acoustic window under resting conditions. All patients underwent dipyridamole echocardiography and exercise ECG -on different days and in random order -within 1 week of coronary angiography (which was performed independent of test results) and were followed up for 37.8 + 14 months (range, 1 to 73 months). Criteria of positivity were for dipyridamole echocardiography, a transient regional dyssynergy absent in the baseline examination; for exercise ECG, an ST-segment shift of .0.1 mV from baseline; and for coronary angiography, a luminal reduction of >75% in at least one major coronary vessel (50% for left main). There were 183 patients without and 246 with coronary artery disease; 132 had one-, 70 had two-, and 44 had three-and/or left main vessel disease. The specificity was higher for dipyridamole echocardiography than for exercise ECG (90% versus 51%, P<.001). The overall S tress echocardiography is being increasingly proposed as a new tool for the diagnosis of coronary artery disease. The low cost, noninvasiveness, and availability of echocardiography make it particularly suitable -as a cardiac imaging modality -to be combined with stressful interventions.' In particular, dipyridamole echocardiography is gaining popularity as an exercise-independent method of diagnosing coronary artery disease. [2] [3] [4] [5] In the initial experience, highdose dipyridamole echocardiography has been shown to be relatively inexpensive, feasible, safe, fast, and highly accurate for the diagnosis of angiographically assessed sensitivity of dipyridamole echocardiography was similar to that of exercise ECG (75% versus 74%, P=NS), with no significant differences in the subset with one-(67% versus 69%, P=NS), two-(79% versus 77%, P=NS), or three-(93% versus 86%, P=NS) vessel disease. During the follow-up, there were 20 deaths, 13 nonfatal myocardial infarctions, and 126 revascularization procedures. In the univariate analysis, dipyridamole resulted in higher x2 values than did exercise stress testing. A Cox forward stepwise survival analysis identified the dipyridamole time as the most powerful prognostic predictor of death (X2=19.4 P<.0001) of all invasive and noninvasive parameters. The dipyridamole time also provided independent and additional prognostic information when it was adjusted for age, diabetes, resting ECG, and exercise stress test according to a modified, interactive stepwise procedure. This is true when death only, death and myocardial infarction, and death, myocardial infarction, and revascularization procedures were considered end points.
Conclusions In patients with no previous myocardial infarction and good resting left ventricular function, compared with exercise ECG, dipyridamole echocardiography has a similar sensitivity and a higher specificity for the noninvasive detection of angiographically assessed coronary artery disease. Dipyridamole echocardiography also provides information in addition to that provided by exercise ECG for predicting death, infarction, and all events when the presence as well as the timing, severity, and extension of dipyridamole-induced wall motion abnormalities are considered. (Circulation. 1994; 89:1160 -1173 Key Words * dipyridamole * echocardiography . ischemia coronary artery disease6-10 as well as for prognostic stratification.1-'4 The diagnostic value of dipyridamoleinduced transient dyssynergy has also been confirmed by other imaging techniques, such as radionuclide ventriculography15""6 and magnetic resonance,17 which are less dependent than two-dimensional echocardiography on operator experience and patient acoustic window, although they are certainly characterized by a lower temporal resolution. Although a considerable amount of information was obtained from this relatively new diagnostic test, much more is needed before it can become an accepted option in clinical practice.1 According to Feinstein,18 a new test is somewhat similar to a new drug, and the initial phase I and II studies in selected populations should be followed by phase III large-scale studies, in which the test is compared with 7000; 2.5-and 3.5-MHz transducers) were used. In the baseline studies as well as during stress, all standard echocardiographic views were obtained when possible. During the test, new areas of abnormal wall motion were identified in multiple views whenever possible. The videotapes were analyzed by the cardiologist-echocardiographist performing the test, who was blind to the clinical and angiographic data. A wall motion score index was derived for rest and peak dipyridamole echocardiograms in each patient. The left ventricle was divided into 11 segments according to segmentation already adopted in the EPIC multicenter trial subproject on residual ischemia.23 The 11 left ventricular segments considered for analysis were apex, proximal and distal anterior septum, proximal and distal inferior septum, proximal and distal anterior wall, proximal and distal lateral wall, and proximal and distal inferior wall.
Segmental wall motion was graded as normal, normal motion at rest with normal/increased wall motion (hyperkinesis) after dipyridamole (score, 1); hypokinetic, marked reduction in endocardial motion (score, 2); akinetic, virtual absence of inward motion (score, 3); or dyskinetic, paradoxical wall motion away from the left ventricular center in systole (score, 4). The wall motion score index was derived by summation of individual segment scores divided by the number of interpreted segments. Inadequately visualized segments were not scored. In positive tests, the dipyridamole time, ie, minutes from the beginning of drug infusion to the development of the stress-induced dyssynergy, was also evaluated. In negative tests, the dipyridamole time was 
Feasibility and Safety
No major side effects occurred during either exercise ECG or dipyridamole echocardiography in any patient. In all patients, the quality of echocardiograms was unchanged during dipyridamole echocardiography and therefore suitable for analysis. However, in three patients, the higher dose could not be administered be- When 0.1-mV ST-segment shift was chosen as a cutoff between negative and positive exercise stress testing, dipyridamole echocardiography had a superior specificity (90% versus 51%, P<.001), whereas the two tests showed a similar sensitivity for the detection of angiographically assessed coronary artery disease (dipyridamole echocardiography, 75%; exercise ECG, 74%; P=NS). Of the 72 patients with coronary artery disease and negative exercise ECG, 18 (25%) did not reach 85% of target heart rate, predicted on the basis of age and sex. Excluding from the analysis patients with submaximal testing, the sensitivity of exercise ECG increased to 80%. The specificity of exercise was substantially lower than that of dipyridamole in both men and women (P<.001), in patients with abnormalities of the resting ECG, and in patients with normal resting ECG (P<.001) ( Table 3 ). The sensitivity was comparable in the different subsets of patients with one-, two-, and three-vessel disease (Table 3) .
In patients with one-vessel disease, the sensitivity was similar in patients with isolated left anterior descending, left circumflex, and right coronary artery disease (Table  3 ). In patients with one-vessel disease, dipyridamole echocardiography sensitivity was similar to that of exer- cise ECG for patients with 75% stenosis, 90% stenosis, and 100% occlusion (Table 3) .
When 0.15-mV ST-segment shift was taken as a cutoff between negative and positive exercise stress testing, the sensitivity of exercise stress decreased to 71% (CI, 66 to 77.4), whereas the specificity increased to 59% (CI, 47.8 to 62). Prognostic Data
Patients were followed up for a period ranging from 1 to 73 months (mean, 37.8±.14 months). During the follow-up, there were 20 deaths (15 cardiac and 5 noncardiac), 13 reported in the curves of Figs 1, 2, and 3 according to the results of exercise ECG and dipyridamole echocardiography, respectively. It should be noted that both exercise and dipyridamole test alone allowed good stratification. In particular, no deaths occurred in the patients with negative exercise ECG and rate-pressure product of >20 000, whereas the death rate at 5 years was 16 .4% in the patients with positive exercise stress testing at a rate-pressure product of <20 000. Survival according to coronary angiography results is reported in Fig. 4 . The variables reported in Table 4 were found to be univariate predictors of death; the dipyridamole time was the most powerful parameter. When a forward stepwise regression procedure was performed, the dipyridamole time, presence of diabetes mellitus, positivity of exercise at low rate-pressure product, and resting ECG were found to be independent and additional predictors of subsequent death (Table 5 ). When variables were entered into the model according to an interactive, clinically realistic approach, after considering age and diabetes as well as resting and exercise ECG, dipyridamole echocardiography added significant prognostic information ( Table 6 ). At that point, coronary angiography did not show significant additional prognostic power.
Also, when survival without infarction and survival without events were considered, dipyridamole echocardiography added prognostic information after taking account of clinical and exercise ECG data. The univariate and multivariate predictors of survival without infarction and survival without events are shown in Tables  7 through 10 .
Discussion
In patients with normal resting function, dipyridamole echocardiography has a similar sensitivity and a higher specificity compared with exercise ECG for the noninvasive detection of angiographically assessed coronary artery disease. The First, the studies were not performed and interpreted by two independent observers; rather, the cardiologistechocardiographist performing the test also interpreted the study. This considerably reduced the time required for evaluating the test results, without any detectable loss in accuracy. The five members of the echocardiographic laboratory staff shared the responsibility of performing and interpreting the test. No detectable differences in diagnostic performance among the observers could be noted, which is consistent with the established notion that accuracy of stress echocardiography is observer dependent but fairly constant in experienced hands. 24 We had already shown that the interobserver and intraobserver reproducibility is very high (>90%) between experienced observers24 and, therefore, that the routine use of separate multiple readings is not cost effective. Nevertheless, in the more realistic conditions of the present study, which are more likely to reproduce those found in a busy echocardiographic laboratory,25 the diagnostic accuracy of dipyridamole echocardiography proved to be very high and not significantly lower than that reported in initial studies on smaller patient series that were evaluated under more controlled conditions. Second, in addition to the presence of the dyssynergy, the analysis of echocardiographic data included an assessment of the timing as well as of the wall motion score index, evaluated both under resting conditions and at peak dipyridamole. This allowed us to evaluate the prognostic correlates of the main echocardiographic parameters potentially capable of quantifying the induced ischemia. 25 We previously showed the high reproducibility of dipyridamole time,27 which is directly correlated to exercise time28 and inversely correlated to the severity of coronary stenosis29 and to the impairment in flow reserve. 30 
Patient Selection
Some features of our patient population should be considered. It has been said that any new diagnostic tool is usually tested, at least initially, in a very select patient population -representing "the wellest of the well and the sickest of the sick," in whom the diagnostic test performance is likely to be better than that in a "real" population. 25 However, in the present study, we selected a consecutive series of patients admitted for diagnostic work-up. In this way, our population probably reflects the continuous spectrum of the disease, and the performance of the test is as close as possible to that found in the real world. This may be why the sensitivity and specificity of both tests are a little lower than those previously reported. In particular, in our population, we recorded an extremely low specificity of exercise ECG, which might appear to be in disagreement with extensive experience with this test.31 This finding might have multiple explanations linked to exercise ECG test data analysis, to angiographic data analysis, and, perhaps most important in our opinion, to patient selection. Regarding exercise ECG data analysis, we restricted positivity criteria to classic ECG criteria, without considering the combination of several other variables, such as heart rate, work load, and so on, that might increase the overall diagnostic power of exercise testing.32 Regarding angiographic assessment, we set the cutoff for significant stenosis at 75% with visual assessment, which means that some patients with "subcritical" stenoses actually might have had "critical" stenoses by quantitative analysis. Patient selection may be another major factor of poor specificity for several reasons. In our study population, there was a relatively high proportion of women and of patients with abnormal baseline ECGs; however, the restriction of analysis either to men or to patients with normal resting ECGs increases specificity only to a limited extent. Of greater importance might have been the presence of a high proportion of patients with microvascular disease or angina of vasospastic origin, in whom-even in the presence of entirely normal coronary arteries -stress-induced STsegment changes are frequently seen during exercise.33 Previous studies from our institution have shown that Moreover, sensitivity was found to be lower when exercise stress testing was compared with a "better" test.3' The main advantages of this prospective technique derive from its capacity to show a complete spectrum of consecutive challenges to which both tests were exposed.18'20 We believe, therefore, that the indexes of diagnostic accuracy reported in this article are likely to mirror exactly how the tests perform under clinical conditions. Another important point is that our population was not receiving therapy. It is known that antianginal therapy may prevent ischemia, in its ECG/ echocardiographic manifestations evoked by either exercise19 or dipyridamole34 testing. Furthermore, our patients had no previous myocardial infarction. Because the inclusion of patients with previous myocardial infarction is known to inflate test sensitivity and the diagnosis of coronary artery disease is not at issue in patients with myocardial infarction, the inclusion of such patients in investigations purporting to predict coronary disease is inappropriate.24,25 The selection of patients from those referred for coronary angiography because of chest pain can explain why the clinical history of angina is not so important in this patient population, whereas it usually is in the general population.
Study Limitations
The gold standard used for comparison of noninvasive test results was the angiographically assessed coronary artery disease. It is known that angiographic stenosis is not necessarily related to the degree of impairment in regional coronary flow reserve. 35 Furthermore, the visual assessment suffers from relatively high intraobserver and interobserver variability.36 Although a subjective visual estimate of "percent stenosis" lacks accuracy and repeatability and does not provide accurate insight into the hemodynamic impact of a lesion, the simplicity of the percent stenosis estimate and the force of tradition favor its continued use36: in most cardiological centers, the visual assessment of coronary stenosis remains the definitive gold standard.
A second limitation is inherent to the sensitivityspecificity approach that we used; this approach requires a dichotomic response for both test results and coronary artery disease when all, in fact, show a continuous spectrum of severity.25 Therefore, in the present study, we also evaluated a few parameters of severity of exercise testing (peak rate-pressure product and exercise time) and of dipyridamole echocardiography response (wall motion score index, dipyridamole time), which proved to be effective in prognostic stratification. Furthermore, for exercise stress testing, we considered stratification into five subgroups, taking into account both different levels of ECG positivity and different levels of rate-pressure product or exercise time; this stratification was found to be more effective in prognostic stratification than presence of ST-segment changes, rate-pressure product, and exercise time considered separately. The stronger predictive power of dipyridamole time in comparison with wall motion score index for the prediction of death might be maxinW LOW RISK It therefore can be reasonably concluded that these two tests, which assess abnormalities in myocardial electrophysiology and cardiovascular efficiency (exercise ECG) and location and severity of ischemia (dipyridamole echocardiography), might be used in combination. This analysis should not be construed as an argument favoring the routine use of a combination of exercise ECG and dipyridamole echocardiography. In the usual patient with the diagnostic dilemma of a chest pain syndrome, systematic application of the two tests may be unfeasible as well as unwise. In terms of pure diagnostic performance, dipyridamole echocardiography did significantly better than exercise ECG. However, one must consider than exercise ECG is by far a less expensive, and more widespread and "routine" procedure than dipyridamole echocardiography, which requires a two-dimensional echocardiograph and personnel with specific expertise in stress echocardiography. Therefore, a rational approach may still be to use exercise ECG as a first-line test and to reserve dipyridamole echocardiography for patients with either a positive at high intermediate workload or a nondiagnostic (with exercise-induced chest pain or submaximal workload achieved during stress) exercise ECG. Also, a markedly positive ECG (with a low workload) is an indication to coronary angiography, without additional testing. Dipyridamole echocardiography is especially indicated in the presence of conditions further reducing the reliability of exercise-induced ECG changes, such as female gender53 or hypertension,54 that do not influence the diagnostic performance of dipyridamole echocardiography. Once dipyridamole echocardiography is performed, the response should be evaluated according to the type of positivity, which may provide important stratification of the ischemic response. This strategy of testing appears to be reasonable in our cost-conscious era in which we face the major challenge of maintaining the highest diagnostic standards in the presence of a substantial decrease in resources. However, it remains to be prospectively validated in another series of patients. The results of this study and others55-57 indicate that the functional consequences, elicited by stress testing, of any given anatomic configuration may have more of an impact on outcome than the mere number of vessels with stenosis when ventricular function is intact.
In conclusion, dipyridamole echocardiography has a similar sensitivity and a higher specificity compared with exercise ECG in patients with normal resting function. Dipyridamole echocardiography does not offer only a binary, black-or-white response but rather complex stratification of the ischemic response with an array of shades of gray, including the extent, severity, and timing of the transient dyssynergy. The severity of the stress-induced ischemia is even more important than its presence in identifying the coronary anatomy and prognostic outlook of a patient.
